Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
Abstract Aims/Introduction The objective of the present study was to elucidate the effect of switching to teneligliptin from other dipeptidyl peptidase‐4 (DPP‐4) inhibitors on glucose control and renoprotection in type 2 diabetes mellitus patients with diabetic kidney disease. Materials and Methods...
Main Authors: | Munehiro Kitada, Yoshio Ogura, Kyoko Nitta, Mizue Fujii, Keizo Kanasaki, Kazunori Konishi, Yasuo Iida, Atsushi Nakagawa, Daisuke Koya |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-05-01
|
Series: | Journal of Diabetes Investigation |
Subjects: | |
Online Access: | https://doi.org/10.1111/jdi.12917 |
Similar Items
-
Teneligliptin in management of type 2 diabetes mellitus
by: Sharma SK, et al.
Published: (2016-08-01) -
Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
by: Ghosh S, et al.
Published: (2016-11-01) -
The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice
by: Takayasu Ideta, et al.
Published: (2015-12-01) -
Renoprotective effects of teneligliptin: An observational study
by: Prabhat Agrawal, et al.
Published: (2021-01-01) -
Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis
by: Takahiro Ozutsumi, et al.
Published: (2020-03-01)